Last reviewed · How we verify

NCT05473637: TAG-SVD

Taiwan Associated Genetic and Nongenetic Small Vessel Disease

Recruiting now Last updated 20 January 2026
What this trial tests

trial testing MRI in Cerebral Small Vessel Diseases in 500 participants. Currently enrolling.

Timeline
1 January 2019
Primary endpoint
31 December 2026
31 December 2028

Quick facts

Lead sponsorNational Taiwan University Hospital
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment500
Start date1 January 2019
Primary completion31 December 2026
Estimated completion31 December 2028
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

National Taiwan University Hospital

Who can join

18 and older, any sex, with Cerebral Small Vessel Diseases or Cadasil. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The TAG-SVD enrolled patients with clinical and neuroimaging features of cerebral small vessel disease (CSVD). All enrolled patients will receive next-generation sequence (NGS) with probes designed to target five candidate CSVD genes, and patients will be divided into genetic or non-genetic groups accordingly. Their clinical features and outcome will be followed for at least 2 years.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of MRI

Trials testing the same drug.

Other recruiting trials for Cerebral Small Vessel Diseases

Currently open trials in the same condition.

Other National Taiwan University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05473637.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing